|Everest Medicines Inc., of New York||Xerava (eravacycline)||Fully synthetic fluorocycline||Complicated intra-abdominal infections||The Health Science Authority in Singapore approved it|
|Hutchison China Meditech Ltd. (Chi-Med), of Hong Kong||Surufatinib||CSF-1 antagonist; FGF1 receptor antagonist; pan-VEGF receptor antagonist||Pancreatic and non-pancreatic neuroendocrine tumors||FDA granted fast track designations|
|Redhill Biopharma Ltd., of Tel Aviv, Israel||Yeliva (opaganib, ABC-294640)||Oral sphingosine kinase-2 selective inhibitor||COVID-19||Submitted IND to FDA for phase IIa trial in up to 60 adults hospitalized with positive SARS-CoV-2 and pneumonia|
|Seattle Genetics Inc., of Bothell, Wash.||Tukysa (tucatinib)||Oral, small-molecule tyrosine kinase inhibitor of HER2||Breast cancer||FDA approved for use in adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received 1 or more prior anti-HER2-based regimens in the metastatic setting; application was reviewed under real-time oncology review pilot program; NDA also part of Project Orbis|
For more information about individual companies and/or products, see Cortellis.